statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical...

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target...

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 29th, there was short...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Black Diamond Therapeutics price target raised by $1 at H.C. Wainwright, here's why

Black Diamond Therapeutics (NASDAQ:BDTX  Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a report issued on Monday, Benzinga...

Black Diamond Therapeutics (NASDAQ:BDTX) Earns Buy Rating from HC Wainwright

BDTX Advances in Oncology with Key Clinical Trials and Maintains Strong Cash PositionRelated Stocks: BDTX...

Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired...

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutationsCAMBRIDGE, Mass., March 05, 2024...

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 21.7% in February

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Drop in Short Interest

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Volume	303.00
52-Wk High	$6.85
52-Wk Low	$1.43

BDTX Black Diamond Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals